insights_auto
Why is CRSP down 2.78%?
Dive Deeperchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
$49.99
arrow_downward
-2.78%(-1.43) 1D
$50.06
arrow_upward
+0.13% (+0.066)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CRSP...
Open
$51.90
High
$52.12
Low
$49.70
Mkt. cap
4.83B
Avg. vol.
1.52M
Volume
1.03M
52-wk high
$64.74
52-wk low
$44.12
EPS
-$4.76
Beta
1.45
Shares outstanding
96.69M
No. of employees
393
Open
$51.90
High
$52.12
Low
$49.70
Mkt. cap
4.83B
Avg. vol.
1.52M
Volume
1.03M
52-wk high
$64.74
52-wk low
$44.12
EPS
-$4.76
Beta
1.45
Shares outstanding
96.69M
No. of employees
393
News stories
From web sources and news partners
Yahoo Finance
·
5 hours ago
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
Securities.io
·
5 hours ago
CRISPR Therapeutics Q3 CASGEVY Revenue Reaches $99 Million
Investing.com Canada
·
5 hours ago
Form 8K CRISPR THERAPEUTICS AG For: 2 November By Investing.com
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, Switzerland
SectorBiotechnology
Websitecrisprtx.com